ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2024; 15(2):545-559. doi:10.7150/jca.90236 This issue Cite
Research Paper
WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer through Activation of Innate Immune Responses
Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
†These authors contributed equally to this work.
Citation:
Li Y, Wang X, Hou X, Wu M, Wang S, Ma X. WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer through Activation of Innate Immune Responses. J Cancer 2024; 15(2):545-559. doi:10.7150/jca.90236. https://www.jcancer.org/v15p0545.htm
Other stylesAbstract
Introduction: Recurrence signifies the primary mortality factor in patients suffering from endometrial cancer, with few efficacious treatments currently available for recurrent cases. This research investigates the anti-tumoral capacities of WEE1 inhibitors within the context of endometrial cancer, aiming to establish a novel therapeutic avenue for high recurrence-risk patients.
Materials and methods: We evaluated WEE1 expression in endometrial cancer patients utilizing immunohistochemistry on paraffin-embedded tissue sections. The cytotoxic potential of WEE1 inhibitors on endometrial cancer cells was assessed by CCK8 assay. Assays to gauge the influence of WEE1 inhibitors on cell proliferation and migration included clonal proliferation, wound healing, and transwell assays. We determined the impacts on apoptosis and cell cycle stages by flow cytometry. Employing qRT-PCR and western blotting, we investigated the mechanistic pathways underlying the anti-tumoral activity of WEE1 inhibitors. In vivo evaluations were executed to ascertain the inhibitory effect of WEE1 inhibitors on tumor growth in mice.
Results: WEE1 exhibited high-level expression in endometrial cancer tissues, particularly pronounced in recurrent compared with non-recurrent patients. WEE1 inhibitors effectively eliminated endometrial cancer cells while inhibiting their proliferation and migration. Flow cytometric analyses revealed a significant promotion of apoptosis and an increase in G2/M phase cell proportion upon WEE1 inhibitor treatment. qRT-PCR and western blotting elucidated that WEE1 inhibitors activated the innate immune signaling pathway in endometrial cancer cells. Furthermore, in vivo assessments demonstrated substantial tumor growth suppression due to WEE1 inhibitors.
Conclusions: WEE1 inhibitors initiated an innate immune response in endometrial cancer, exhibiting considerable anti-tumoral effects, which was promising for postoperative treatment of endometrial cancer, especially recurrent endometrial cancer patients.
Keywords: endometrial cancer, recurrence, target therapy, WEE1 inhibitor, innate immune response
Citation styles
APA
Li, Y., Wang, X., Hou, X., Wu, M., Wang, S., Ma, X. (2024). WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer through Activation of Innate Immune Responses. Journal of Cancer, 15(2), 545-559. https://doi.org/10.7150/jca.90236.
ACS
Li, Y.; Wang, X.; Hou, X.; Wu, M.; Wang, S.; Ma, X. WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer through Activation of Innate Immune Responses. J. Cancer 2024, 15 (2), 545-559. DOI: 10.7150/jca.90236.
NLM
Li Y, Wang X, Hou X, Wu M, Wang S, Ma X. WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer through Activation of Innate Immune Responses. J Cancer 2024; 15(2):545-559. doi:10.7150/jca.90236. https://www.jcancer.org/v15p0545.htm
CSE
Li Y, Wang X, Hou X, Wu M, Wang S, Ma X. 2024. WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer through Activation of Innate Immune Responses. J Cancer. 15(2):545-559.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.